Eli Lilly and Company has announced the appointment of Thomas J. Fuchs, Dr.sc., as its inaugural Chief AI Officer, effective October 21, 2024. In this newly established position, Fuchs will spearhead the vision and strategic direction of AI initiatives across the organization, encompassing drug discovery, clinical trials, manufacturing, and commercial operations. His role will involve the development and management of AI and machine learning solutions aimed at enhancing Lilly's capabilities to deliver innovative medicines globally.
Prior to joining Lilly, Fuchs served as the dean and inaugural chair for AI and Human Health at Mount Sinai and directed the Hasso Plattner Institute for Digital Health. He held key positions at prestigious institutions, including Memorial Sloan Kettering Cancer Center and NASA's Jet Propulsion Laboratory, and is recognized for founding companies such as Paige AI. Fuchs holds a doctoral degree in machine learning from ETH Zurich and brings extensive expertise in leveraging technology for healthcare advancements. Eli Lilly is committed to addressing significant health challenges and improving patient outcomes through innovative solutions in biotechnology and medicine.
